Adalimumab (Humira), the best-selling medication globally, is not worth its current price and doesn’t work as well as 2 of its competitors, according to a new report from the Institute for Clinical and Economic Review (ICER), an independent nonprofit organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures.
Overall, the report concludes, targeted immune-modulating (TIM) rheumatoid arthritis (RA) drugs work better than older treatments such as methotrexate, but the prices of TIMs detracted from ICER’s cost-effectiveness rating, which is based on a quality-adjusted life-year (QALY) analysis. According to ICER, most immune modulators exceed traditional cost/QALY analysis thresholds.
To be designated as cost effective by ICER, adalimumab’s net price would need to be at a 50% to 69% discount of the list price. None of its competitors, tumor necrosis factor (TNF)-alpha or other classes, hit ICER’s benchmark for value, per ICER’s report, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, which was released April 7, 2017.
AbbeVie, the maker of adalimumab, has taken issue with the report’s conclusions and said ICER’s methodology was flawed. Analysts say that while the report is not likely to have much of an effect on adalimumab’s sales for now, it might affect pricing decisions on forthcoming novel medications and the need for those novel medications with payers. The report could potentially also affect pricing on adalimumab’s biosimilars when they are marketed.
Humira had the highest per-QALY cost of the TNF-alpha inhibitors at $232,644; infliximab (Remicade) came in the lowest at $202,824. Tocilzumab (Actemra), an IL-6 inhibitor, had the lowest overall cost at $168,600 per-QALY cost. ICER’s report noted that based on head-to-head data on effectiveness versus adalimumab, etanercept (Enbrel) was comparable in lowering disease activity; certolizumab (Cimzia) and abatacept (Orencia) matched on a variety of measures. Tocilzumab was superior to Humira at decreasing disease activity and on one common assessment scale.
The report also included comparative analyses of 2 investigational RA drugs, baricitinib (Olumiant, JAK inhibitor) and sarilumab (Kevzara, an IL-6 inhibitor), which were superior to Humira at lowering disease activity and 2 other assessment tools.
ICER’s effectiveness analyses gave Humira a “C” rating. ICER’s endorsement for moderate certainty of incremental or better benefit generally requires that a treatment receive a B+ grade.
The report concludes that although all the TIMs evaluated substantially improved health outcomes compared with conventional disease-modifying antirheumatic drugs (DMARDs) alone, their additional cost led to cost-effectiveness estimates that were well above commonly cited thresholds for cost-effectiveness, and the discounts required to achieve these thresholds are greater than estimated current discounts from wholesale acquisition costs. Compared with the market leader adalimumab, most TIMs in combination with conventional DMARDs were more favorable (lower costs and higher QALYs), ICER said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.